Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...

French drug major Sanofi (SNY) announced Monday that its Sarclisa has obtained first approval in China for the treatment of adult ...

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

The trial enrolled 531 adult subjects with multiple myeloma who had received at least one previous line of therapy.

China NMPA approves Sanofi’s Sarclisa in combo with pomalidomide and dexamethasone to treat adult patients with R/R multiple myeloma: Paris Tuesday, January 14, 2025, 10:00 Hrs ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

A team of researchers from the Translational Oncology Research Centre (TORC) of Vrije Universiteit Brussel (VUB), in ...

(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least ...